SAN CARLOS, Calif., Dec. 19, 2017 /PRNewswire/ -- Prescient Surgical, Inc., a medical device innovator dedicated to developing advanced tools and technologies to prevent surgical site infections (SSIs), announced that the U.S. Food and Drug Administration (FDA) has cleared the CleanCision™ Wound Retraction and Protection System (CleanCision™ System) for commercialization in the United States.

Developed by surgeons and infection control experts, CleanCision(TM) is the first in a new class of advanced technology, combining wound protection and irrigation into an easy-to-use retraction system that has been shown to reverse and reduce the pervasive sources of surgical infection, clearing harmful bacteria throughout surgery when the threat of wound contamination is at its highest.
Developed by surgeons and infection control experts, CleanCision(TM) is the first in a new class of advanced technology, combining wound protection and irrigation into an easy-to-use retraction system that has been shown to reverse and reduce the pervasive sources of surgical infection, clearing harmful bacteria throughout surgery when the threat of wound contamination is at its highest.
Developed by surgeons and infection control experts, CleanCision is the first in a new class of advanced technology designed to fight and defend against the most pervasive sources of surgical infection. Utilizing active cleansing technology, CleanCision combines wound protection and irrigation into an intuitive and easy-to-use retraction system that actively, consistently, and continuously clears harmful bacteria that may invade the incision during surgery.
Unlike traditional methods, which cannot continuously and consistently clear contamination from the surgical site, CleanCision has been shown to reverse and reduce these pervasive sources of infection, clearing harmful bacteria throughout surgery when the threat of wound contamination is at its highest.1

"The threat of incision infection in high risk abdominal surgery presents a constant threat with the potential to adversely impact patient outcomes and drive up health care costs for hospitals," said Dr. Mark Welton, MD, chief medical officer, Fairview Health Services, former Harry A. Oberhleman Jr., professor of surgery and chief of colon and rectal surgery at Stanford University School of Medicine, Palo Alto, Calif., and cofounder of Prescient Surgical, Inc. "CleanCision can put more control over the root causes of infection into the hands of surgical teams, enhancing their current infection control protocols," he added.

Operating Room Homepage